Business Wire

THALES

Share
French Armed Forces to Rely on Thales Expertise to Expand Their Secure Satellite Communication Capabilities

Thales has been chosen by the French defence procurement agency (DGA) to lead a second part of the ground segment of the Syracuse IV satellite communications system for the French armed forces. The Group was selected to supply the satellites in 2015 and to lead the first increment of the ground segment in 2019. This second capacity increment will enhance the interoperable communications capabilities of the French Army, Navy and Air Force in terms of data rate, availability, threat resistance and end-to-end connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005759/en/

Military satellite communications are more critical than ever and more vulnerable to attack; they are at the heart of the battle for strategic independence across all areas of military invention. Maintaining connectivity is key to the armed forces' ability to share information of all types between command centres and units deployed on any type of mission, including coalition operations.

This crucial programme milestone will enhance the performance of the ground segment across all theatres of operation for the three branches of the French military. The Thales solution will decisive in meeting the capacity requirements of land, naval and air force programmes such as Scorpion, FREMM, FDI, Barracuda, aircraft carrier, or Rafale. It aims to increase tenfold the secure communication capabilities of fighting vehicles on the move, surface vessels, submarines, and now also aircrafts. The Thales technology guarantees roaming communications in both X- and Ka-band and fully exploits the multi-spot potential of High Throughput Satellite (HTS) technology.

All the ground terminals in the system will be able to make optimum use of the Syracuse IV constellation. Their full interconnection via new docking terminals will allow considerable increase in data rate by ensuring joint cooperation in theatres of operations and with command centres. They will also be compatible with third-party satellite resources, depending on the area of deployment, without compromising communications security.

To achieve this objective, Thales will leverage its high-level systems integration expertise, and in particular its highly secure Modem 21 transmission system, to guarantee the availability and confidentiality of all communications and provide protection from the full spectrum of threats with no impact on operational performance, which is key to retaining information superiority in high-intensity combat. Thales’s NATO-standard Modem 21 solution has been proven in combat for over ten years.

The role of Thales Alenia Space in this contract will include mission management for the Syracuse constellation and management of the anchoring capabilities of the operator, the French Defence Ministry's joint infrastructure networks and information systems agency (DIRISI). Thales Alenia Space is also lead contractor for the contract notified by the DGA at the end of 2015 for the supply of the space segment consisting of the Syracuse 4A and 4B satellites and their control and mission ground segment.

Building on its expertise as a technology orchestrator and integrator for satellite communication systems in France and internationally, Thales has deployed over 1,000 secure, protected satcom stations worldwide, working with local industrial partners.

“As prime contractor for the Syracuse III and Syracuse IV ground segments since 2004, Thales is proud to strengthen its partnership with the French Ministry for the Armed Forces to help maintain the informational superiority of the country’s armed forces in highly contested environments. The sovereign satcom solutions to be supplied under this contract are resilient to all types of threats, combat-proven, and fully interoperable with the systems deployed by NATO coalition forces.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales.

Note to editors

Syracuse is a series of protected telecommunication satellites designed to ensure that the French armed forces can communicate at all times between mainland France and units deployed around the world. The Syracuse programme provides a fully independent solution to France’s wide-ranging requirements for long-range, secure communication capabilities that are protected against electronic warfare threats. Three generations of Syracuse satellites were deployed between 1984 and 2015. The Syracuse IV programme will replace the Syracuse 3A and Syracuse 3B satellites currently in orbit, while delivering an expanded and upgraded network of ground stations. A constellation of two satellites has been ordered under the first phase of the Syracuse IV programme. They will be built by Thales Alenia Space and Airbus Defence and Space. The first satellite will enter service in 2022.

About Thales

Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers – businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.

With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).

PLEASE VISIT

Thales Group

Download photos

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye